CVT 3833
Latest Information Update: 10 Feb 2003
At a glance
- Originator CV Therapeutics
- Class
- Mechanism of Action Partial fatty acid oxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris; Heart failure
Most Recent Events
- 10 Feb 2003 No development reported - Preclinical for Angina pectoris in USA (unspecified route)
- 10 Feb 2003 No development reported - Preclinical for Congestive heart failure in USA (unspecified route)
- 06 Jun 2001 Preclinical development for Angina pectoris in USA (Unknown route)